Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology 2018; 125: 842–9 CrossRef MEDLINE 10. Heier JS, Lad EM ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

Occasionally, treatments come along that are of greater interest to patients than to doctors.Drops for treating presbyopia ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

The charity has described the UK medicine regulator’s decision not to approve Syfovre as “undoubtedly disappointing news” ...